ProQR Therapeutics BV Earnings
The next earnings date for ProQR Therapeutics BV has not yet been scheduled.
Analyst Estimates of ProQR Therapeutics BV Earnings
| No results. | |
What is an Earnings Date
An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.
Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.
Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.
ProQR Therapeutics BV Earnings: Historical
| 08/20/2026 | --- | $-0.10 | 28.57% |
| 05/12/2026 | Before Market | $-0.15 | 16.67% |
| 02/19/2026 | --- | $-0.09 | -4.63% |
| 11/06/2025 | Before Market | $-0.12 | 29.41% |
| 08/07/2025 | Before Market | $-0.14 | -75.00% |
| 05/08/2025 | Before Market | $-0.11 | 31.25% |
| 03/13/2025 | --- | $-0.09 | 4.86% |
| 11/07/2024 | Before Market | $-0.08 | 42.86% |
| 08/08/2024 | Before Market | $-0.04 | 76.47% |
| 05/09/2024 | Before Market | $-0.10 | 37.50% |
More About ProQR Therapeutics BV
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
“ProQR Therapeutics BV Earnings” Can Refer to the ProQR Therapeutics BV Earnings Date
Some people say “ProQR Therapeutics BV earnings” as a shortform way to refer to the earnings date.
For example, someone might say, “I plan to hold my ProQR Therapeutics BV position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.
Owning ProQR Therapeutics BV Stock on the Earnings Date
If you own ProQR Therapeutics BV stock (PRQR) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.
A company’s earnings typically have a big impact on its stock price, which explains why the stock price for ProQR Therapeutics BV might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.
There is often a big audience of investors involved with trading ProQR Therapeutics BV shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.
These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.
Learning More ProQR Therapeutics BV Earnings
You can contact us any time if you would like to ask questions about ProQR Therapeutics BV earnings or anything else related to the stock market.